Summary

Organization name

Profile

Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, commercialize and manufacture biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and over 50 projects in the pipeline. The company is the leading provider of anti-tumor therapeutics in the United States.

Genentech's research organization focuses its efforts on basic and applied science in

• Oncology
  • solid tumors and hematology
  • anti-angiogenic agents
  • anti-morphogenic agents
  • antibody-drug conjugates
  • cell cycle inhibitors
  • monoclonal antibodies
  • pro-apoptotic drugs
  • small molecule protein kinase inhibitors
• Immunology
  • autoimmune and inflammatory diseases, mulitple sclerosis, theumatoid arthritis, asthma, lupus, psoriasis, inflammatory bowel disease
  • novel immunoregulatory targets
  • therapeutic antibodies for infectious diseases
• Disorders of Tissue Growth and Repair
  • cardio-vascular diseases
  • ophthalmic disease, age-related macular degeneration, diabetic macular edema, glaucoma
  • critical care therapies
  • metabolic disorders, insulin resistance, Type II diabetes, associated vascular disease
  • wound healing
• Technology
  • antibody generation, selection, and optimization
  • biomarker discovery, as well as disease diagnosis or imaging (PET, CT, MRI)
  • medicinal chemistry and related technologies
  • novel drug delivery formulations and systems
  • protein expression and purification
  • unique models of disease

Developing alliances has been one of Genentech's key strategies for success from its inception. Several marketed products and products in clinical development have arisen from successful collaborations. Genentech considers collaborations wherever there is excellent science and the potential for a good strategic fit. Genentech is dedicated to bringing considerable resources to the alliance, and is open to different collaboration structures. Genentech has the resources of a large company, including world-class research, clinical, and sales and marketing expertise, but has retained the energy and drive of a small, growing company.

GenenFUND Genentech has a corporate venture capital fund, GenenFUND, that identifies and invests in companies with compelling technologies and/or drug candidates that are too early for licensing.

Additional information and contact data are provided online and in the attached pdf.

Description File

URL

Your feedback

back